Drug Profile
Research programme: central nervous system disorders therapeutics - Janssen Pharmaceutica/BBB Therapeutics
Latest Information Update: 07 Oct 2014
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer BBB Therapeutics; Janssen Pharmaceutica
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 07 Oct 2014 No development reported for CNS disorders in Europe (IV)
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics